News

ELCC: Survey reveals worldwide underuse of EGFR-mutation testing


 

AT ELCC 2015

References

The survey was sponsored by Boehringer Ingelheim. Dr. Spicer has been an advisor to and speaker on behalf of Boehringer Ingelheim and had received research funding from the company. Dr. Mok has been a consultant to and speaker on behalf of Boehringer Ingelheim as well as several other drug companies.

mzoler@frontlinemedcom.com

On Twitter @mitchelzoler

Pages

Recommended Reading

Outcomes worse for lung cancer patients with VTE
MDedge Internal Medicine
Palliative surgery eases pain at end of life
MDedge Internal Medicine
VIDEO: Circulating tumor DNA testing shows real-world limits
MDedge Internal Medicine
Three-dimensional models show superiority of nanoparticles in mesothelioma
MDedge Internal Medicine
ELCC: NSCLC mutation testing highlights ctDNA’s limitations
MDedge Internal Medicine
New agent targets EGFR resistance in NSCLC
MDedge Internal Medicine
Rociletinib active against resistant NSCLC
MDedge Internal Medicine
ELCC: Urine tumor DNA shows high testing promise
MDedge Internal Medicine
Statin use associated with reduced lung cancer mortality
MDedge Internal Medicine
VIDEO: Level of e-cigarette power contributes to potentially hazardous effects
MDedge Internal Medicine